Literature DB >> 10508711

Monoclonal antibody drug conjugates in the treatment of cancer.

P A Trail1, A B Bianchi.   

Abstract

Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugated to drugs with different mechanisms of action and different levels of potency. Monoclonal-antibody-directed drug delivery has the potential to both improve efficacy and reduce systemic toxicity. Several immunoconjugates have demonstrated impressive antigen-specific antitumor activity in preclinical models. Phase I trials of a calicheamicin immunoconjugate for treatment of acute myeloid leukemia and a doxorubicin immunoconjugate for treatment of carcinoma have recently been completed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10508711     DOI： 10.1016/s0952-7915(99)00012-6

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  10 in total

1.  Design of a minimal protein oligomerization domain by a structural approach.

Authors:  P Burkhard; M Meier; A Lustig
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

Review 2.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

3.  Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate.

Authors:  J A G van Roon; J W J Bijlsma; J G J van de Winkel; F P J G Lafeber
Journal:  Ann Rheum Dis       Date:  2004-11-11       Impact factor: 19.103

4.  Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Authors:  Motoo Nagane; Saki Shimizu; Eiji Mori; Shiro Kataoka; Yoshiaki Shiokawa
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

5.  BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models.

Authors:  Leslie L Muldoon; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

Review 6.  Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.

Authors:  Ali Raufi; Abdul Shukkur Ebrahim; Ayad Al-Katib
Journal:  Cancer Manag Res       Date:  2013-08-27       Impact factor: 3.989

7.  Natural and non-natural amino-acid side-chain substitutions: affinity and diffraction studies of meditope-Fab complexes.

Authors:  Krzysztof P Bzymek; Kendra A Avery; Yuelong Ma; David A Horne; John C Williams
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-10-24       Impact factor: 1.056

Review 8.  Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer.

Authors:  Nasrul Wathoni; Lisa Efriani Puluhulawa; I Made Joni; Muchtaridi Muchtaridi; Ahmed Fouad Abdelwahab Mohammed; Khaled M Elamin; Tiana Milanda; Dolih Gozali
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

9.  Floridoside extracted from the red alga Mastocarpus stellatus is a potent activator of the classical complement pathway.

Authors:  Anthony Courtois; Christelle Simon-Colin; Claire Boisset; Christian Berthou; Eric Deslandes; Jean Guézennec; Anne Bordron
Journal:  Mar Drugs       Date:  2008-07-10       Impact factor: 5.118

10.  Meditope-Fab interaction: threading the hole.

Authors:  Krzysztof P Bzymek; Yuelong Ma; Kendra N Avery; David A Horne; John C Williams
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-11-18       Impact factor: 1.056
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.